Lead Product(s) : NT-0796
Therapeutic Area : Immunology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
NodThera's NT-0796 Meets Primary Endpoint in Inflammation Reversal in Obese Subjects
Details : NT-0796 is an oral, brain-penetrant NLRP3 inflammasome inhibitor, being investigated on inflammation in obese participants at risk of cardiovascular disease.
Product Name : NT-0796
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 06, 2024
Lead Product(s) : NT-0796
Therapeutic Area : Immunology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : QEL-001
Therapeutic Area : Immunology
Study Phase : Phase I/ Phase II
Sponsor : eXmoor pharma
Deal Size : Undisclosed
Deal Type : Partnership
Quell Therapeutics Expands CAR-Treg Manufacturing with eXmoor Pharma
Details : Quell & eXmoor are partnering on the process transfer, scale-up, and Phase 1/2 clinical manufacturing of multiple autologous CAR-Treg cell therapies, including QEL-001, for liver transplant patients.
Product Name : QEL-001
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
September 24, 2024
Lead Product(s) : QEL-001
Therapeutic Area : Immunology
Highest Development Status : Phase I/ Phase II
Sponsor : eXmoor pharma
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : QEL-001
Therapeutic Area : Immunology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Quell's QEL-001 CAR-Treg Therapy Moves to Phase 1/2 Trial for Liver Transplant Patients
Details : QEL-001, its autologous engineered CAR-Treg cell therapy, which is being investigated in Phase 1/2 trial in patients with liver transplant patients.
Product Name : QEL-001
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
April 06, 2024
Lead Product(s) : QEL-001
Therapeutic Area : Immunology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : EXS4318
Therapeutic Area : Immunology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : EXS4318 is a PKC theta inhibitor which plays a critical role in controlling T cell function and is a key driver of several highly prevalent autoimmune diseases. PKC theta inhibitors have potential in inflammatory and immunologic diseases.
Product Name : EXS4318
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 02, 2023
Lead Product(s) : EXS4318
Therapeutic Area : Immunology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable